The thiol compound amifostine has been demonstrated to reduce the incidence of dry mouth when used during the radiotherapy course of patient undergoing radiotherapy that encompasses the salivary glands – particularly the parotids, as these provide 80% of the saliva. This observation is one of some importance as the recent introduction of chemo-radiotherapy programmes for this disease has led to increased toxicity; research aimed at reducing toxicity is much in demand.
